Shionogi to divest Japanese pharma manufacturing operation
This article was originally published in Scrip
Executive Summary
Shionogi has reached an agreement to sell a domestic wholly owned pharmaceutical contract manufacturing subsidiary to a Japanese private equity fund, as part of an ongoing effort to focus on its core business of developing and marketing prescription drugs.